|Brand names||Aldazine, Meleril, Mellaril, Melleril and others.|
Thioridazine is a phenothiazine typical antipsychotic used to treat schizophrenia that has been voluntarily (that is, the drug company sponsoring it was the one that withdrew it, not the drug regulators) withdrawn from the worldwide market (except for the U.S.A. market),[note 1] as it was felt that its benefits did not outweigh its risk when used to treat schizophrenia. Compared to other first-generation antipsychotics, especially the phenothiazines, it is notably devoid of antiemetic activity. It has recently been developed as a treatment for resistant cases of tuberculosis.
- NCBI Bookshelf provides free book resources on this topic.
- PubMed provides review articles from the past five years (limit to free review articles or to systematic reviews)
- The TRIP database provides clinical publications about evidence-based medicine.
- ↑ By 'worldwide market' I am solely referring to English-speaking countries
- ↑ Brayfield, A, ed. (13 December 2013). "Thioridazine". Martindale: The Complete Drug Reference. London, UK: Pharmaceutical Press. Retrieved 23 August 2014.
- ↑ Amaral, L (March-April 2012). "Thioridazine: an old neuroleptic effective against totally drug resistant tuberculosis.". Acta Medica Portuguesa 25 (2): 118–21. PMID 22985923. Check date values in: